4 recruiting, 3 unknown, 1 not yet recruiting, 1 suspended. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 4, Unknown 3, Not yet recruiting 1, Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow GATA2 Deficiency: new trials by email Literature Review of GATA2 Deficiency trials Research Report on GATA2 Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-08-15 | 2026-11-03 |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 30 | 2024-08-22 | 2026-06-30 |
| A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS APL-4098, Azacitidine and APL-4098, Azacitidine and Venetoclax and APL-4098 - Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia | Phase 1 | Recruiting | Apollo Therapeutics Ltd | 100 | 2024-06-04 | 2026-10-28 |
| A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome QLF32101 - Acute Myeloid Leukemia and Myelodysplastic Syndrome | Phase 1 | Unknown | Qilu Pharmaceutical Co., Ltd. | 122 | 2023-02-01 | 2023-01-31 |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia AB8939, Venetoclax - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | AB Science | 78 | 2022-06-01 | 2025-10-02 |
| A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS BS HH 002.SA - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Unknown | Shanghai Bensen Pharmaceutical Co., Ltd. | 66 | 2021-02-01 | 2021-02-08 |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide Nivolumab - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 | Withdrawn | SCRI Development Innovations, LLC | 2020-04-13 | 2023-12-05 | |
| Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant Nivolumab, Ipilimumab - Acute Myeloid Leukemia and Myelodysplastic Syndrome | Phase 1 | Terminated | Hackensack Meridian Health | 8 | 2019-03-08 | 2024-11-18 |
| A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications NKR-2 cells - Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM) | Phase 1 / Phase 2 | Unknown | Celyad Oncology SA | 146 | 2016-12-01 | 2019-09-19 |
Leukemia, Myeloid, Acute (7) · Myelodysplastic Syndromes (3) · Anemia, Refractory, with Excess of Blasts (1) · Graft vs Host Disease (1) · Leukemia, Myelomonocytic, Chronic (1) · Multiple Myeloma (1)
Bone Marrow Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Myelodysplastic Syndromes (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Leukemia (7) · Leukemia, Myeloid (7) · Immune System Diseases (2) · Anemia (1) · Anemia, Refractory (1) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
venetoclax (4) · Azacitidine (3) · Specimen Handling (3) · Nivolumab (2) · Biopsy (1) · Ipilimumab (1) · decitabine and cedazuridine drug combination (1) · iadademstat (1) · posaconazole (1) · regorafenib (1)
AB Science (1) · Apollo Therapeutics Ltd (1) · Celyad Oncology SA (1) · City of Hope Medical Center (1) · Hackensack Meridian Health (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Qilu Pharmaceutical Co., Ltd. (1) · SCRI Development Innovations, LLC (1) · Servier (1) · Shanghai Bensen Pharmaceutical Co., Ltd. (1)
United States (7) · Australia (1) · Belgium (1) · China (1) · France (1) · Greece (1) · Spain (1) · United Kingdom (1)
Andrew Pecora, MD (1) · Curtis A Lachowiez (1) · Evan C Chen (1) · James McCloskey, MD (1) · Jamie Koprivnikar, MD (1) · Nicholas Short, MD (1) · Norbert Vey, MD (1) · Paul Koller (1) · Sanjay Aggarwal, MD (1)
PMID 29133316, PMID 36764323, PMID 42013378
2025 (1), P30CA033572 (1), UM1CA186709 (1)